Overview

Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)

Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.
Phase:
Phase 4
Details
Lead Sponsor:
Southeast Retina Center, Georgia
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept